Aura Biosciences (NASDAQ:AURA) stockholders approved the company’s two annual meeting proposals Thursday, re-electing two directors and ratifying the company’s outside auditor for fiscal 2026.
The biotechnology company held its 2026 virtual annual meeting of stockholders on June 11. Natalie Holles, Aura’s chief executive officer and president, called the meeting to order and presided over the formal business. Conor Kilroy, the company’s chief legal officer and secretary, was asked to record the minutes.
Quorum Established
The company reported that 64,199,778 shares of common stock were entitled to vote at the meeting. According to the meeting operator, at least 52,784,744 shares were represented by proxy, establishing a quorum.
Stockholders who had logged in through the virtual meeting platform using a 16-digit control number were able to vote and submit questions. The company said no questions were received regarding either proposal presented during the formal portion of the meeting.
Directors Re-Elected
The first proposal before stockholders was the election of two Class 2 directors to serve three-year terms. Aura’s board nominated David Johnson and Teresa Marie Bitetti for election.
Holles said Aura’s bylaws require advance notice from stockholders seeking to nominate director candidates, and that no such notice had been received. The board unanimously recommended that stockholders vote in favor of the proposal.
The inspector of election reported that a plurality of shares present or represented and entitled to vote were cast in favor of the nominees. Holles then declared the proposal approved by stockholders.
Auditor Ratification Approved
The second proposal was the ratification of Ernst & Young LLP as Aura’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Holles said the appointment was made by the audit committee of the board, which is comprised entirely of independent directors. The board approved the selection and submitted it to stockholders for ratification as a matter of good corporate governance, even though stockholder ratification is not required by the company’s bylaws.
The inspector of election reported that a majority of the shares present or represented and entitled to vote were cast in favor of ratifying Ernst & Young LLP. Holles declared that all proposals presented at the meeting had been ratified or approved.
No Other Business Presented
The meeting did not include additional business, operational updates or a question-and-answer session beyond the formal proposal process. Holles said the final voting results, including any ballots and proxies recorded during the meeting, would be set forth in the inspector of election’s report and included in the meeting minutes.
After the voting results were announced, Holles adjourned the meeting.
About Aura Biosciences (NASDAQ:AURA)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
